MOH

Kitchen Brains Empowers Appliance OEMs with MoH™ Innovation: Liz Spina Joins the Team

Retrieved on: 
Friday, April 5, 2024
MOH, Culture, Syracuse University, Business development, Original equipment manufacturer, History, OEM, Restaurant

This strategic move reinforces Kitchen Brains' unwavering dedication to empowering Original Equipment Manufacturers (OEMs) in the commercial kitchen space and driving the future of Middle of House™ (MoH) connected kitchen technology.

Key Points: 
  • This strategic move reinforces Kitchen Brains' unwavering dedication to empowering Original Equipment Manufacturers (OEMs) in the commercial kitchen space and driving the future of Middle of House™ (MoH) connected kitchen technology.
  • "That's why our strategy centers on partnering with leading appliance OEMs and enabling Korrect Technology in every appliance.
  • "I am thrilled to join the Kitchen Brains team where we foster a culture of technical industry leadership and customer excellence," says Liz Spina.
  • Kitchen Brains remains committed to being a trusted partner for OEMs navigating the rapidly evolving landscape of commercial kitchen technology.

Kitchen Brains Empowers Appliance OEMs with MoH™ Innovation: Liz Spina Joins the Team

Retrieved on: 
Friday, April 5, 2024
MOH, Culture, Syracuse University, Business development, Original equipment manufacturer, History, OEM, Restaurant

This strategic move reinforces Kitchen Brains' unwavering dedication to empowering Original Equipment Manufacturers (OEMs) in the commercial kitchen space and driving the future of Middle of House™ (MoH) connected kitchen technology.

Key Points: 
  • This strategic move reinforces Kitchen Brains' unwavering dedication to empowering Original Equipment Manufacturers (OEMs) in the commercial kitchen space and driving the future of Middle of House™ (MoH) connected kitchen technology.
  • "That's why our strategy centers on partnering with leading appliance OEMs and enabling Korrect Technology in every appliance.
  • "I am thrilled to join the Kitchen Brains team where we foster a culture of technical industry leadership and customer excellence," says Liz Spina.
  • Kitchen Brains remains committed to being a trusted partner for OEMs navigating the rapidly evolving landscape of commercial kitchen technology.

Koning Health Achieves UAE Regulatory Clearance, Paving the Way for Breast CT Commercialization in the Middle East

Retrieved on: 
Wednesday, February 28, 2024
Woman, Ministry, MOH, Female, Growth, Perseverance, Ministry of Health, FANR, MEA, Medical imaging

Maher Bannourah, Director of Koning International, led the initiative by leveraging his industry experience with Ministry of Health (MOH) representatives.

Key Points: 
  • Maher Bannourah, Director of Koning International, led the initiative by leveraging his industry experience with Ministry of Health (MOH) representatives.
  • This regulatory approval positions Koning as the first company to introduce breast CT technology in the UAE, setting a new standard in breast imaging and care in the region.
  • "Koning is honored to be accepted as the only approved breast CT in the UAE.
  • The company is excited to embark on this new chapter of growth and innovation in the UAE and beyond.

Italy Compact Construction Equipment Market Assessment 2023-2029: Caterpillar, Volvo CE, Komatsu, JCB, CNH Industrial, SANY, and Hitachi Lead with Strong Market Share and Diverse Equipment Offers

Retrieved on: 
Tuesday, January 9, 2024
Lithium, Bed, Wind, Electricity, Government, National Institute of Statistics, Carbon, EIB, CNH Industrial, Energy, Growth, CO2, City, Volvo, MOH, Brenner Base Tunnel, Caterpillar, Mundi, Octopus Energy, Leonardo da Vinci–Fiumicino Airport, Housing, Komatsu, JCB, Hydrogen, MIMIS, Hospital, Plant, Ministry, Rail transport by country, M4, Natural gas, Environment, Metro, Coal, Hitachi Construction Machinery, USD, Red Circle, Infrastructure, Internet of things, Renewable energy

The Italy compact construction equipment market is expected to grow at a CAGR of 4.89% from 2022 to 2029.

Key Points: 
  • The Italy compact construction equipment market is expected to grow at a CAGR of 4.89% from 2022 to 2029.
  • In addition, the growth in renovation and road construction projects is expected to drive the demand for compact earthmoving equipment in the Italy compact construction equipment market.
  • Caterpillar, Volvo CE, Komatsu, JCB, CNH Industrial, SANY, and Hitachi Construction Machinery are front runners in the Italy compact construction equipment market.
  • Compact forklifts accounted for the Italy compact construction equipment market's largest market in 2022.

Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Wednesday, January 3, 2024
Liver, Arch, AKI, Risk, Reperfusion, IRI, Prevalence, Disease, Mortality, TMX Group, Science Advances, Inflammation, National Research Council, Oxygen, Acute kidney injury, OTCQB, CABG, Ministry, Health Canada, Kidney, Injury, Patient, Ischemia, MOH, Pharmaceutical industry

TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • With the Ministry of Health (MoH) approval for the trial, Arch can now proceed to contract and activate clinical sites in Turkey.
  • Once blood flow is restored to normal (reperfusion), inflammation is triggered and injury to kidney cells is exacerbated.

Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on: 
Thursday, December 21, 2023
Clinical trial, Liver, Arch, AKI, Conlon, Reperfusion, Risk, IRI, Prevalence, Ethics, Disease, Mortality, TMX Group, Science Advances, Cardiopulmonary bypass, Inflammation, CPB, Renal replacement therapy, National Research Council, Oxygen, Acute kidney injury, OTCQB, CABG, MOH, Health Canada, Kidney, Injury, Patient, Ischemia, Dialysis, Pharmaceutical industry

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The ethics committee approval of the trial will be followed by a final regulatory review conducted by the Turkish Ministry of Health (MoH), expected to be completed by mid-January.
  • Once the trial is approved by the MoH, activation of clinical sites in Turkey will take place and patient enrollment can begin in February.
  • Quote from Richard Muruve, CEO of Arch Biopartners Inc:
    “We look forward to a positive decision from the MoH, which will permit enrollment of Turkish cardiac surgery patients into the trial.

Lunit to Advance Singapore's Healthcare System with AI-powered Solution for Medical Imaging

Retrieved on: 
Thursday, November 30, 2023
Ministry, Health, CGH, Hospital, Bed, MOH, Patient, Medical imaging, Algorithm, SGH, National health insurance, Therapy, Singapore General Hospital, INSIGHT, Diagnosis, NTT DATA, SingHealth, Health care, Changi General Hospital, AI, NTT, Ministry of Health, Medical device, Nursing, Innovation

As part of the agreement, Lunit collaborated with CARPL to provide NTT DATA with Lunit INSIGHT CXR.

Key Points: 
  • As part of the agreement, Lunit collaborated with CARPL to provide NTT DATA with Lunit INSIGHT CXR.
  • AimSG allows public healthcare institutions to integrate AI imaging solutions, like Lunit INSIGHT CXR, seamlessly into their existing clinical radiology workflow, enhancing medical professionals' diagnostic capabilities and efficiency.
  • Healthcare institutions that have adopted Lunit's AI solution through AimSG have had a positive response and are looking forward to improving the medical imaging workflow.
  • "The AimSG platform enables clinicians from public healthcare institutions to deploy AI algorithms to help them deliver better healthcare to the population.

Knight Therapeutics Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023
DLBCL, Research, MOH, ANVISA, Bank, Lenalidomide, FGFR2, S&M, Thrombocytopenia, LATAM, Health maintenance organization, Fostamatinib, EBITDA, G&A, News, R, ASCT, Hallmark-Sonali Bank Loan Scam, Growth, IAS, Marketing, ITP, USD, Investment, Patient, GBT, Lymphoma, Financial adviser, Pharmaceutical industry, Fine chemical, Bookkeeping, Cryptocurrency, Knight, Novartis, Bancolombia

Gross margin: For the quarter ended September 30, 2023, gross margin, as a percentage of revenues, was 49% compared to 42% in Q3-22.

Key Points: 
  • Gross margin: For the quarter ended September 30, 2023, gross margin, as a percentage of revenues, was 49% compared to 42% in Q3-22.
  • Selling and marketing (“S&M”): For the quarter ended September 30, 2023, S&M expenses were $11,924, a decrease of $1,532 or 11%, compared to the same period in prior year.
  • General and administrative (“G&A”): For the quarter ended September 30, 2023, G&A expenses were $11,080, an increase of $664 or 6%, compared to the same period in prior year.
  • For the quarter ended September 30, 2023, interest income was $3,055, an increase of $593 or 24%, compared to the same period in prior year.

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on: 
Friday, September 22, 2023
Conlon, CABG, Prevalence, Science Advances, Acute kidney injury, Oxygen, MOH, OTCQB, CPB, Arch, IRI, Inflammation, Ethics committee, AKI, Dialysis, Data monitoring committee, Cardiopulmonary bypass, Ministry, Ischemia, Investigational New Drug, Patient, TMX Group, Risk, Renal replacement therapy, Disease, Kidney, Ministry of Health (Kuwait), Reperfusion, Liver, Mortality, FDA, Food, Safety, National Research Council, Pharmaceutical industry, Hospital

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • This application in Turkey follows the Company’s submission of an Investigational New Drug Application to the U.S. Food and Drug Administration’s (FDA).
  • The FDA subsequently granted the Company permission to proceed with this Phase II trial in late June .
  • Of this total, the application to the MoH requests permission to recruit up to 150 patients in Turkey.

Malaysia Showcases Its World-Class Healthcare Offerings at Oman Health 2023

Retrieved on: 
Wednesday, September 20, 2023
Society, Mayo Clinic, Accreditation, Quality, Hospital, Retirement, ACHS, Patient, Ministry of Health (Malaysia), Neurology, Convention center, JCI, Joint Commission, Oman Convention and Exhibition Centre, Social media, Safety, Endocrinology, Health care, Rehabilitation, Government, Ministry, Ethics, White paper, MOH, Sultan of Oman's Armed Forces, Bandar Sunway, Fertility, Healthcare Information and Management Systems Society, Cardiology, Pharmaceutical industry, Nursing, Conference, Health

MUSCAT, Oman, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Malaysia Healthcare is showcasing its world-class healthcare offerings to Omanis, at the annual Oman Health Exhibition and Conference (OHEC), held at the Oman Convention & Exhibition Centre in Muscat.

Key Points: 
  • MUSCAT, Oman, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Malaysia Healthcare is showcasing its world-class healthcare offerings to Omanis, at the annual Oman Health Exhibition and Conference (OHEC), held at the Oman Convention & Exhibition Centre in Muscat.
  • Malaysia Healthcare Travel Council (MHTC), an agency under the Ministry of Health (MOH) Malaysia entrusted to facilitate and promote Malaysia’s healthcare travel industry, together with several leading private hospitals in the country are present at the Malaysian Pavillion, under the brand ‘Malaysia Healthcare’ from 18th to 20th September 2023 at booth No.
  • For comprehensive information on Malaysia Healthcare and its services, including healthcare travel, visit https://malaysiahealthcare.org/ .
  • Stay updated with Malaysia Healthcare by following our social media accounts on Facebook at http://www.facebook.com/malaysiahealthcare.org and on LinkedIn through the Malaysia Healthcare Travel Council.